<DOC>
	<DOCNO>NCT01331837</DOCNO>
	<brief_summary>This randomize , open-label , parallel-group , multicenter study evaluate rate cardiovascular event tocilizumab comparison etanercept participant rheumatoid arthritis ( RA ) . Participants randomize receive intravenous ( IV ) 8 milligram per kilogram ( mg/kg ) tocilizumab every 4 week subcutaneous 50 milligram ( mg ) etanercept weekly , without non-biologic disease-modifying anti-rheumatic drug ( DMARD ) .</brief_summary>
	<brief_title>A Study Tocilizumab Comparison Etanercept Participants With Rheumatoid Arthritis Cardiovascular Disease Risk Factors</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Participants moderate severe RA great equal ( &gt; =6 ) month duration Inadequate response least one nonbiologic DMARD Positive Rheumatoid Factor ( RF ) and/or anticyclic citrullinated peptide ( CCP ) antibodies screen Have Creactive protein ( CRP ) great ( &gt; ) 0.3 milligram per deciliter ( mg/dL ) screen baseline visit Swollen joint count ( SJC ) &gt; =8 ( 66 joint count ) tender joint count ( TJC ) &gt; = 8 ( 68 joint count ) screen baseline visit History Coronary Heart Disease ( CHD ) presence one additional CHD risk factor , include current cigarette smoking , hypertension , low High Density Lipoprotein ( HDL ) cholesterol , family history premature CHD , diabetes , presence extraarticular disease associate rheumatoid arthritis At time randomization , discontinue infliximab , adalimumab , golimumab , certolizumab &gt; = 4 week Major surgery ( include joint surgery coronary revascularization ) within 8 week prior screen plan major surgery within 1 year study start Rheumatic autoimmune disease RA History current inflammatory joint disease RA Current recent ( within past 3 month ) evidence serious uncontrolled concomitant cardiovascular cerebrovascular disease ( myocardial infarction , revascularization , stroke , transient ischemic attack , acute coronary syndrome ) Current previous ( within past 2 year ) evidence serious uncontrolled concomitant pulmonary ( include obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) gastrointestinal disease Uncontrolled disease state , asthma inflammatory bowel disease flare commonly treated oral parenteral corticosteroid Preexisting central nervous system demyelinate seizure disorder History diverticulitis , diverticulosis require treatment low gastrointestinal tract condition might predispose perforation Current liver disease determine investigator ; history asymptomatic elevation liver function test ( LFTs ) consider exclusion Active current infection history recurrent bacterial , viral , fungal , mycobacterial infection , include limited tuberculosis atypical mycobacterial disease , hepatitis B C , herpes zoster , exclude fungal infection nail bed Any major episode infection require hospitalization treatment IV antibiotic within four week screen oral antibiotic within two week prior screen visit Active tuberculosis ( TB ) require treatment within 3 year prior baseline Latent TB diagnose screen appropriately treat Primary secondary immunodeficiency ( history currently active ) Moderate severe heart failure Evidence active malignant disease , malignancy diagnose within previous 10 year ( include hematologic malignancy solid tumor , except basal cell carcinoma skin excise cure ) , breast cancer diagnose within previous 20 year Breast feeding mother History alcohol , drug chemical abuse within 6 month prior screen Participants lack peripheral venous access Participants history allergic reaction latex Previous treatment nontumor necrosis factor ( nonTNF ) inhibitor biologic therapy Treatment investigational agent within 4 week screen visit Treatment cell deplete therapy within 1 year baseline Treatment IV gamma globulin , plasmapheresis Prosorba column within 6 month baseline visit Immunization live/attenuated vaccine within 4 week prior baseline visit Any previous treatment alkylating agent , cyclophosphamide chlorambucil , total lymphoid irradiation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>